CRDF beat EPS expectations by 9.22%
Nov 08, 2024, 11:31 AM
0.00%
What does CRDF do
Cardiff Oncology, based in San Diego, develops drugs targeting mitosis for cancer treatment, focusing on PLK1 inhibition. Its lead candidate, Onvansertib, is undergoing five clinical trials for various cancers.
Cardiff Oncology (CRDF) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Cardiff Oncology's actual EPS was -$0.25, beating the estimate of -$0.28 per share, resulting in a 9.22% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.